Fieldview Capital Management LLC Makes New Investment in Cencora, Inc. $COR

Fieldview Capital Management LLC bought a new position in Cencora, Inc. (NYSE:COR) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,637 shares of the company’s stock, valued at approximately $891,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Barclays PLC grew its stake in Cencora by 2.7% in the 4th quarter. Barclays PLC now owns 388,469 shares of the company’s stock worth $131,205,000 after acquiring an additional 10,248 shares during the period. Black Creek Investment Management Inc. grew its stake in Cencora by 8.7% in the 4th quarter. Black Creek Investment Management Inc. now owns 46,725 shares of the company’s stock worth $15,781,000 after acquiring an additional 3,734 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in Cencora by 22.5% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,247,968 shares of the company’s stock worth $421,501,000 after acquiring an additional 229,291 shares during the period. Jacobi Capital Management LLC purchased a new stake in Cencora in the 4th quarter worth approximately $583,000. Finally, FORA Capital LLC purchased a new stake in Cencora in the 4th quarter worth approximately $1,271,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Performance

NYSE:COR opened at $281.56 on Monday. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The firm has a market capitalization of $54.78 billion, a price-to-earnings ratio of 21.59, a PEG ratio of 1.52 and a beta of 0.59. The firm’s fifty day simple moving average is $289.22 and its 200 day simple moving average is $327.32. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The business had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities research analysts expect that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were issued a dividend of $0.60 per share. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. Cencora’s payout ratio is presently 18.40%.

Cencora declared that its board has authorized a stock buyback plan on Thursday, May 21st that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 3.9% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on COR shares. Robert W. Baird decreased their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. William Blair started coverage on shares of Cencora in a report on Tuesday, April 28th. They issued a “market perform” rating on the stock. Barclays decreased their price target on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a report on Wednesday. Leerink Partners reiterated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Finally, Wells Fargo & Company decreased their price target on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a report on Monday, May 11th. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $374.00.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.